生物活性 | |||
---|---|---|---|
描述 | Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is the first orally active inhibitor targeting the androgen receptor (AR) N-terminal domain (NTD). It is effective against both the full-length AR and variants associated with resistance, such as AR-v7[1][2]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.92mL 0.38mL 0.19mL |
9.60mL 1.92mL 0.96mL |
19.19mL 3.84mL 1.92mL |
参考文献 |
---|